Overview

Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
Phase1 study of TTC 352 for treatment of metastatic ER+ breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
TTC Oncology, LLC
Treatments:
Estrogens